OncoMatch/Clinical Trials/NCT05553782

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

Is NCT05553782 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Implantable Microdevice (IMD) for salivary gland cancer.

Early Phase 1RecruitingBrigham and Women's HospitalNCT05553782Data as of May 2026

Treatment: Implantable Microdevice (IMD) — This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: \-- implantable microdevice

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Excluded: Stage IV, ADVANCED, INCURABLE

without evidence of recurrent, metastatic or advanced, incurable disease undergoing definitive surgical management; any stage disease is permitted (American Joint Committee on Cancer 2017 8th edition)

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

platelet count ≥50,000/mcl, pt/inr <2, and aptt <1.5x upper limit of normal

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Brigham and Women's Hospital · Boston, Massachusetts
Dana Farber Cancer Institute · Boston, Massachusetts

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify